← Human Trials & Peer-Reviewed Studies
Effect of insulin aspart combined with insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus
Plain-language guide to PMID 40049655 (2025): randomized controlled trial study of Insulin Aspart and Insulin Detemir in 96 patients.
Key Facts
- PMID
- 40049655
- Journal
- Journal of drug targeting
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Wang H et al. (5 authors)
- DOI
- 10.1080/1061186X.2025.2477074
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Insulin Aspart and Insulin Detemir.
This trial evaluated the effects of insulin aspart (IAsp) and insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus (T2DM).
The study compared clinical outcomes, as well as changes in fasting plasma glucose (FPG), 2-hour postprandial blood glucose (PBG), glycated haemoglobin (HbA1c), fasting insulin (FINS), homeostasis model assessment of insulin resistance (HOMA-IR), HOMA-β, quality of life, and sleep quality scores before and after treatment.
Who Took Part
The study group was 96 patients.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
A total of 96 T2DM patients were randomised into the control group (insulin detemir + metformin treatment) and the study group (insulin detemir + metformin + IAsp treatment), with 48 cases each.
How the Study Was Run
The researchers set it up as a randomized study.
Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.
What Was Measured
This trial evaluated the effects of insulin aspart (IAsp) and insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus (T2DM).
The study compared clinical outcomes, as well as changes in fasting plasma glucose (FPG), 2-hour postprandial blood glucose (PBG), glycated haemoglobin (HbA1c), fasting insulin (FINS), homeostasis model assessment of insulin resistance (HOMA-IR), HOMA-β, quality of life, and sleep quality scores before and after treatment.
The subject headings attached to it are Diabetes Mellitus, Type 2, Metformin, Insulin Detemir, Hypoglycemic Agents, Insulin Aspart, Blood Glucose and Quality of Life.
Author keywords: Type 2 diabetes mellitus, adverse reactions and islet function.
What This Means in Plain Language
The paper is a randomized study of Insulin Aspart and Insulin Detemir in 96 patients.
The publication is from 2025 (Journal of drug targeting), a journal based in England.
More context: the Insulin Aspart compound page and the Insulin Detemir compound page, all human trials.
Our Notes on the Compounds
Insulin Aspart: A rapid-acting mealtime insulin analog; brands include NovoLog, NovoRapid and Fiasp.
Insulin Detemir: A long-acting basal insulin analog sold as Levemir.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.